Effective November 28, 2023, Aeglea BioTherapeutics, Inc. will change its Nasdaq Capital Market stock ticker symbol to SYRE from AGLE.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.3 USD | -0.23% | +6.37% | +73.93% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.16% | 1.51B | |
+7.65% | 113B | |
+10.98% | 106B | |
+0.41% | 22.27B | |
-11.91% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-6.04% | 17.24B | |
+6.84% | 14.29B | |
+35.83% | 12.52B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea BioTherapeutics, Inc. will Change its Ticker to SYRE from AGLE